Dihydropyridomycins 2 and 3, which lack the characteristic enol ester moiety of the potent antimycobacterial natural product pyridomycin (1), have been prepared from L-Thr, R-and S-hydroxy isovaleric acid, and 3-pyridinecarboxaldehyde. The 2R isomer 2 shows only 4-fold lower anti-Mtb activity than 1, indicating that the enol ester moiety in the natural product is not critical for its biological activity. This finding establishes 2 as a potent and more practical lead for anti-TB drug discovery.KEYWORDS: natural products, InhA, pyridomycin, total synthesis, tuberculosis T uberculosis (TB) is a frequently fatal infectious disease that causes more than 1.4 million deaths annually. TB was considered to be well contained in the 1960s, but recent decades have witnessed a resurgence of the disease, even in industrialized countries, due to comorbidity with AIDS and the emergence of multi-and extensively drug-resistant (MDR, XDR) strains of the causative pathogen Mycobacterium tuberculosis (Mtb). 1 These developments were paralleled by a decline in TB-directed drug discovery efforts; thus, as of today, the last TB drug with a novel mode of action was launched more than 40 years ago, and current combination therapy is insufficient to eliminate XDR Mtb. 2 As a consequence, there is an urgent need for the development of new anti-TB agents that can shorten the duration of treatment (current standard first line therapy of TB extends over 6 months) and/or are active against MDR and XDR bacteria.Pyridomycin (1) (Chart 1) is a bacterial natural product that was first isolated from the Streptomyces strain 6706 in 1953. 3,4 The compound was subsequently shown to exhibit significant in vitro antimycobacterial activity and low systemic toxicity in mice. 5 While these findings were not further explored for decades to come, we have recently confirmed the in vitro antimycobacterial activity of 1, which we found to inhibit Mtb growth with a minimal inhibitory concentration (MIC) of 0.3 μg/mL. 6 Moreover, we have identified the molecular target of 1 as the mycobacterial NADH-dependent enoyl-[acyl-carrierprotein] reductase (InhA), 6 which is also the target of the clinical TB drug isoniazid (INH) (after metabolic activation and formation of a NADH adduct as the effective inhibitory species). 7,8 Pyridomycin (1) is a competitive inhibitor at the NADH-binding site of InhA but has not shown cross-resistance with INH. 6 This suggests that the exact molecular interactions of 1 with the NADH-binding site differ from those of the NADH adduct of INH. Together with the fact that the structure of 1 does not resemble any known TB drug, these findings render pyridomycin an auspicious starting point for TB drug discovery.Only a single total synthesis of 1 has been reported in the literature; significant difficulties were encountered in that work 9 with regard to the establishment of the enol ester double bond between C2 and C1′, 10 a problem that could not be solved in a fully satisfactory manner. In light of these difficulties, we felt th...